explore -WSS

explore

author：Wikipedia 2025-08-12 08:29:27 - browse：848

Adobe

LONDON — Merck said Wednesday it is buying ophthalmology-focused startup EyeBio in a deal worth up to $3 billion, as the pharma company looks to diversify its pipeline.

Under the deal, Merck, through a subsidiary, will pay $1.3 billion in cash upfront, with another $1.7 billion potentially included if certain regulatory and commercial milestones are met. The Wall Street Journal first reported the news Tuesday night.

EyeBio has been developing a drug called restoret for a number of retinal diseases, including age-related macular degeneration and diabetic macular edema. It presented data in February from a Phase 1/2 trial of restoret in both conditions. Merck said it plans to move restoret into a pivotal trial for diabetic macular edema later this year.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Listen: PBM conflicts, RSV vaccines, & the future of flu season

knowledge

entertainment

WSS

4th of July breaks record for highest global temperature ever measured

ARCH Venture Partners tops STAT's 2023 biotech VC rankings

WHO calls for emergency meeting on new China virus, as cases spread

EHR maker NextGen Healthcare to pay $31M to resolve fraud claims

Group opposing PBM reform sets lobbying record

These geoengineering technologies could help combat the climate crisis, scientists say

explore

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Wikipedia

In age of alternative facts, a scholarly course on calling out crap

Key House panel plots a new health care package

Moonlake's readout produced a cash windfall. Risks remain

Doctors find melanoma drugs effective against rare brain cancer

United colonoscopy coverage change 'may cost lives,' doctors say

Biden tests positive for Covid

As demand for Covid shots wanes, Moderna seeks its next success

Key House panel plots a new health care package

Virginia high school admissions case could be legal follow

As digital health tech proliferates, a new institute aims to cut through hype

leisure time

Custom gene therapy hints at new path for rare disease treatments

Australia's humpback populations rebound raising hopes of marine scientists

Key House panel plots a new health care package

Group opposing PBM reform sets lobbying record

FDA approves RSV monoclonal antibody for infants, toddlers

Whistleblower: Blue Cross Blue Shield evaded $170 million in taxes

focus

knowledge

entertainment

entertainment